Tecan and Technoclone; a Collaboration for the University Children’s Hospital in Zurich
News May 08, 2009
Application specialists from Tecan have teamed up with Technoclone GmbH, Vienna, and the University Children’s Hospital in Zurich to validate the TECHNOTHROMBIN® thrombin generation assay (TGA) for Tecan’s Infinite® M200 multimode microplate reader.
Dr Oliver Speer, head of the Experimental Hematology and Erythrocyte Laboratory at the hospital, explained: “We installed the Infinite reader in our laboratory to standardize all of our photometric assays using just a single platform. Once we had completed the transfer of our existing assays to the Infinite, we realized that the flexibility and sensitivity of the instrument would allow us to supersede some of these assays with more efficient or sensitive methods, so became interested in the TECHNOTHROMBIN TGA.”
“Representatives from Tecan and Technoclone came to the hospital to assist with development and validation of this assay on the Infinite reader, enabling us to very quickly complete our validation study. The collaboration between the two companies was perfect for us, and we are still in regular contact with Tecan for technical assistance. The support we have received has been excellent, and Tecan has even developed the software specifically for our needs.”
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE